- In September 2024, Boehringer Ingelheim International GmbH announced that the FIBRONEER-IPF trial met its primary endpoint of FVC improvement at week 52, and it plans to submit a new drug application for nerandomilast for IPF treatment to the FDA and other Asia-Pacific authorities. This successful trial and upcoming submission will strengthen Boehringer Ingelheim’s position in the competitive IPF market, potentially expanding its respiratory drug portfolio
- In November 2022, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced a new collaboration with Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences and achieve quality objectives. This has helped the company to expand Asia-Pacific
- In March 2022, Genentech, a member of the Roche Group announced that the Phase III SKYSCRAPER-02 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq (atezolizumab) and chemotherapy (carboplatin and etoposide) as an initial (first-line) treatment for people with extensive-stage small cell lung cancer (ES-SCLC), did not meet its co-primary endpoint of progression-free survival. This has helped the company to expand Asia-Pacific
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
5 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET, REGULATIONS
5.1 NORTH AMERICA
5.1.1 U.S.
5.1.2 CANADA
5.2 EUROPE
5.2.1 EUROPEAN UNION (EMA - EUROPEAN MEDICINES AGENCY)
5.2.2 GERMANY (FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES - BFARM)
5.2.3 UNITED KINGDOM (MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY - MHRA)
5.3 ASIA-PACIFIC
5.3.1 JAPAN (PMDA - PHARMACEUTICALS AND MEDICAL DEVICES AGENCY)
5.3.2 CHINA (NMPA - NATIONAL MEDICAL PRODUCTS ADMINISTRATION)
5.3.3 AUSTRALIA (TGA - THERAPEUTIC GOODS ADMINISTRATION)
5.4 LATIN AMERICA
5.4.1 BRAZIL (ANVISA - BRAZILIAN HEALTH REGULATORY AGENCY)
5.4.2 ARGENTINA (ADMINISTRACIÓN NACIONAL DE MEDICAMENTOS, ALIMENTOS Y TECNOLOGÍA MÉDICA - ANMAT)
5.5 MIDDLE EAST AND AFRICA (MEA)
5.5.1 UNITED ARAB EMIRATES (UAE - MINISTRY OF HEALTH AND PREVENTION)
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF FIBROTIC DISEASES
6.1.2 INCREASE IN THE NUMBER OF PEOPLE SMOKING CIGARETTES
6.1.3 TECHNOLOGICAL ADVANCEMENT IN THE TREATMENT OF FIBROSIS DISEASES
6.1.4 AWARENESS AND EARLY DIAGNOSIS INITIATIVES
6.2 RESTRAINTS
6.2.1 HIGH COST OF MEDICATION AND TREATMENTS
6.2.2 LACK OF EFFECTIVE BIOMARKERS AND DIAGNOSTIC TOOLS FOR EARLY DETECTION AND MONITORING OF FIBROTIC DISEASES
6.3 OPPORTUNITIES
6.3.1 RISING RESEARCH AND DEVELOPMENT ACTIVITIES
6.3.2 ADVANCEMENTS IN PIPELINE DRUG DEVELOPMENTS
6.3.3 INCREASING STRATEGIC COLLABORATIONS AND PARTNERSHIPS
6.4 CHALLENGES
6.4.1 THE COMPLEX AND MULTIFACTORIAL NATURE OF FIBROTIC DISEASES.
6.4.2 HIGH RATE OF FAILURE IN CLINICAL TRIALS FOR FIBROTIC DISEASES,
7 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT
7.1 OVERVIEW
7.2 MEDICATION
7.2.1 MEDICATION, BY TREATMENT
7.2.2 MEDICATION, BY DISTRIBUTION CHANNEL
7.3 ORGAN TRANSPLANT
7.4 OXYGEN THERAPY
7.5 OTHERS
8 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 IDIOPATHIC PULMONARY FIBROSIS
8.3 HEPATIC CIRRHOSIS
8.4 RENAL FIBROSIS
8.5 CUTANEOUS FIBROSIS
8.6 OTHERS
9 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 SPECIALTY CLINICS
9.4 ACADEMIC AND RESEARCH INSTITUTES
9.5 OTHERS
10 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET, BY REGION
10.1 ASIA PACIFIC
11 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET, COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
12 SWOT ANALYSIS
13 COMPANY PROFILE
13.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
13.1.1 COMPANY SNAPSHOT
13.1.2 REVENUE ANALYSIS
13.1.3 COMPANY SHARE ANALYSIS
13.1.4 PRODUCT PORTFOLIO
13.1.5 RECENT DEVELOPMENTS
13.2 GENENTECH, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD)
13.2.1 COMPANY SNAPSHOT
13.2.2 COMPANY SHARE ANALYSIS
13.2.3 PRODUCT PORTFOLIO
13.2.4 RECENT DEVELOPMENTS
13.3 TEVA PHARMACEUTICAL INDUSTRIES LTD.
13.3.1 COMPANY SNAPSHOT
13.3.2 REVENUE ANALYSIS
13.3.3 COMPANY SHARE ANALYSIS
13.3.4 PRODUCT PORTFOLIO
13.3.5 RECENT DEVELOPMENTS
13.4 SANDOZ INTERNATIONAL GMBH
13.4.1 COMPANY SNAPSHOT
13.4.2 COMPANY SHARE ANALYSIS
13.4.3 PRODUCT PORTFOLIO
13.4.4 RECENT DEVELOPMENTS
13.5 ACCORD HEALTHCARE
13.5.1 COMPANY SNAPSHOT
13.5.2 COMPANY SHARE ANALYSIS
13.5.3 PRODUCT PORTFOLIO
13.5.4 RECENT DEVELOPMENTS
13.6 ABBVIE INC.
13.6.1 COMPANY SNAPSHOT
13.6.2 REVENUE ANALYSIS
13.6.3 PRODUCT PORTFOLIO
13.6.4 RECENT DEVELOPMENTS
13.7 BRISTOL-MYERS SQUIBB COMPANY.
13.7.1 COMPANY SNAPSHOT
13.7.2 REVENUE ANALYSIS
13.7.3 PRODUCT PORTFOLIO
13.7.4 RECENT DEVELOPMENTS
13.8 BIOMX.
13.8.1 COMPANY SNAPSHOT
13.8.2 PRODUCT PORTFOLIO
13.8.3 RECENT DEVELOPMENTS
13.9 INTERCEPT PHARMACEUTICALS, INC.
13.9.1 COMPANY SNAPSHOT
13.9.2 REVENUE ANALYSIS
13.9.3 PRODUCT PORTFOLIO
13.9.4 RECENT DEVELOPMENTS
13.1 KITHER BIOTECH S.R.L.
13.10.1 COMPANY SNAPSHOT
13.10.2 PRODUCT PORTFOLIO
13.10.3 RECENT DEVELOPMENTS
13.11 REDX PHARMA PLC.
13.11.1 COMPANY SNAPSHOT
13.11.2 REVENUE ANALYSIS
13.11.3 PRODUCT PORTFOLIO
13.11.4 RECENT DEVELOPMENTS
13.12 VERONA PHARMA PLC
13.12.1 COMPANY SNAPSHOT
13.12.2 REVENUE ANALYSIS
13.12.3 PRODUCT PORTFOLIO
13.12.4 RECENT DEVELOPMENTS
14 QUESTIONNAIRE
15 RELATED REPORTS
List of Table
TABLE 1 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 2 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 3 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 4 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, 2018-2032 (VOLUME)
TABLE 5 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, 2018-2032 (ASP)
TABLE 6 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 7 ASIA-PACIFIC ORGAN TRANSPLANT IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 8 ASIA-PACIFIC OXYGEN THERAPY IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 9 ASIA-PACIFIC OTHERS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 10 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 11 ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 12 ASIA-PACIFIC HEPATIC CIRRHOSIS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 13 ASIA-PACIFIC RENAL FIBROSIS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 14 ASIA-PACIFIC CUTANEOUS FIBROSIS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 15 ASIA-PACIFIC OTHERS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 16 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 17 ASIA-PACIFIC HOSPITALS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 18 ASIA-PACIFIC SPECIALTY CLINICS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 19 ASIA-PACIFIC ACADEMIC AND RESEARCH INSTITUTES IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 20 ASIA-PACIFIC OTHER END-USE IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 21 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 22 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 23 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 24 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 25 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 26 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 27 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 28 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 29 JAPAN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 30 JAPAN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 31 JAPAN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 32 JAPAN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 33 JAPAN FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 34 JAPAN FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 35 JAPAN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 36 CHINA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 37 CHINA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 38 CHINA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 39 CHINA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 40 CHINA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 41 CHINA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 42 CHINA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 43 INDIA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 44 INDIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 45 INDIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 46 INDIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 47 INDIA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 48 INDIA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 49 INDIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 50 SOUTH KOREA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 51 SOUTH KOREA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 52 SOUTH KOREA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 53 SOUTH KOREA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 54 SOUTH KOREA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 55 SOUTH KOREA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 56 SOUTH KOREA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 57 AUSTRALIA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 58 AUSTRALIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 59 AUSTRALIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 60 AUSTRALIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 61 AUSTRALIA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 62 AUSTRALIA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 63 AUSTRALIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 64 SINGAPORE FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 65 SINGAPORE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 66 SINGAPORE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 67 SINGAPORE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 68 SINGAPORE FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 69 SINGAPORE FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 70 SINGAPORE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 71 THAILAND FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 72 THAILAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 73 THAILAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 74 THAILAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 75 THAILAND FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 76 THAILAND FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 77 THAILAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 78 MALAYSIA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 79 MALAYSIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 80 MALAYSIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 81 MALAYSIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 82 MALAYSIA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 83 MALAYSIA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 84 MALAYSIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 85 INDONESIA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 86 INDONESIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 87 INDONESIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 88 INDONESIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 89 INDONESIA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 90 INDONESIA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 91 INDONESIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 92 PHILIPPINES FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 93 PHILIPPINES MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 94 PHILIPPINES MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 95 PHILIPPINES MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 96 PHILIPPINES FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 97 PHILIPPINES FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 98 PHILIPPINES MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 99 VIETNAM FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 100 VIETNAM MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 101 VIETNAM MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 102 VIETNAM MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 103 VIETNAM FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 104 VIETNAM FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 105 VIETNAM MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 106 TAIWAN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 107 TAIWAN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 108 TAIWAN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 109 TAIWAN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 110 TAIWAN FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 111 TAIWAN FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 112 TAIWAN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 113 REST OF ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
List of Figure
FIGURE 1 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: SEGMENTATION
FIGURE 11 EXECUTIVE SUMMARY
FIGURE 12 STRATEGIC DECISIONS
FIGURE 13 INCREASING PREVALENCE OF CHRONIC DISEASES IS DRIVING THE GROWTH OF THE ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET FROM 2025 TO 2032
FIGURE 14 THE MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET IN 2025 AND 2032
FIGURE 15 MARKET OVERVIEW
FIGURE 16 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, 2024
FIGURE 17 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, 2025-2032 (USD THOUSAND)
FIGURE 18 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, CAGR (2025-2032)
FIGURE 19 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 20 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: BY APPLICATION, 2024
FIGURE 21 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: BY APPLICATION, 2025-2032 (USD THOUSAND)
FIGURE 22 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: BY APPLICATION, CAGR (2025-2032)
FIGURE 23 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 24 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: BY END USER, 2024
FIGURE 25 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: BY END USER, 2025-2032 (USD THOUSAND)
FIGURE 26 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: BY END USER, CAGR (2025-2032)
FIGURE 27 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 28 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: SNAPSHOT (2024)
FIGURE 29 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: COMPANY SHARE 2024 (%)
